Dawson James analyst Jason Kolbert maintained a Hold rating on Caladrius Biosciences (CLBS – Research Report) on August 5. The company’s shares closed last Friday at $0.51.
Kolbert covers the Healthcare sector, focusing on stocks such as Sorrento Therapeutics, Can-Fite BioPharma, and Citius Pharmaceuticals. According to TipRanks, Kolbert has an average return of -0.9% and a 36.50% success rate on recommended stocks.
Caladrius Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $6.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $1.34 and a one-year low of $0.40. Currently, Caladrius Biosciences has an average volume of 164.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.
Read More on CLBS:
- Dawson James Sticks to Their Buy Rating for Profire Energy (PFIE)
- Vuzix (VUZI) Gets a Buy from Dawson James
- Goldman Sachs Keeps Their Hold Rating on Weave Communications (WEAV)
- Jefferies Reaffirms Their Hold Rating on Sharp (SHCAY)
- Analysts’ Opinions Are Mixed on These Technology Stocks: Dynatrace (DT), Aurora Innovation (AUR) and Altice Usa (ATUS)
